TY - JOUR
T1 - Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study
AU - Marasco, Giovanni
AU - Colecchia, Antonio
AU - Bacchi Reggiani, Maria Letizia
AU - Celsa, Ciro
AU - Farinati, Fabio
AU - Giannini, Edoardo Giovanni
AU - Benevento, Francesca
AU - Rapaccini, Gian Ludovico
AU - Caturelli, Eugenio
AU - Di Marco, Mariella
AU - Di Marco, Maria Teresa
AU - Biasini, Elisabetta
AU - Marra, Fabio
AU - Morisco, Filomena
AU - Foschi, Francesco Giuseppe
AU - Zoli, Marco
AU - Gasbarrini, Antonio
AU - Baroni, Gianluca Svegliati
AU - Masotto, Alberto
AU - Sacco, Rodolfo
AU - Raimondo, Giovanni
AU - Azzaroli, Francesco
AU - Mega, Andrea
AU - Vidili, Gianpaolo
AU - Brunetto, Maurizia Rossana
AU - Nardone, Gerardo
AU - Dajti, Elton
AU - Ravaioli, Federico
AU - Avanzato, Francesca
AU - Festi, Davide
AU - Trevisani, Franco
PY - 2021
Y1 - 2021
N2 - Background: Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients. Aims: To evaluate the accuracy of the available prognostic models for HCC to predict the survival of advanced HCC patients treated with Sorafenib included in the Italian Liver Cancer (ITA.LI.CA.) multicenter cohort. Methods: The performance of several prognostic scores was assessed through a Cox regression-model evaluating the C-index and the Akaike Information Criterion (AIC). Results: Data of 1129 patients were analyzed. The mean age of patients was 61.6 years, and 80.8% were male. During a median follow-up period of 13 months, 789 patients died. The median period of Sorafenib administration was 4 months. All the prognostic scores were able to predict the overall survival (p<0.001) at univariate analysis, except the Albumin-Bilirubin score. The Italian Liver Cancer score (CLIP) yielded the highest accuracy (C-index 0.604, AIC 9898), followed by the ITA.LI.CA. prognostic score (C-index 0.599, AIC 9915). Conclusions: The CLIP score had the highest accuracy in predicting the overall survival of HCC patients treated with Sorafenib, although its performance remained poor. Further studies are needed to refine the current ability to predict the outcome of HCC patients undergoing Sorafenib.
AB - Background: Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients. Aims: To evaluate the accuracy of the available prognostic models for HCC to predict the survival of advanced HCC patients treated with Sorafenib included in the Italian Liver Cancer (ITA.LI.CA.) multicenter cohort. Methods: The performance of several prognostic scores was assessed through a Cox regression-model evaluating the C-index and the Akaike Information Criterion (AIC). Results: Data of 1129 patients were analyzed. The mean age of patients was 61.6 years, and 80.8% were male. During a median follow-up period of 13 months, 789 patients died. The median period of Sorafenib administration was 4 months. All the prognostic scores were able to predict the overall survival (p<0.001) at univariate analysis, except the Albumin-Bilirubin score. The Italian Liver Cancer score (CLIP) yielded the highest accuracy (C-index 0.604, AIC 9898), followed by the ITA.LI.CA. prognostic score (C-index 0.599, AIC 9915). Conclusions: The CLIP score had the highest accuracy in predicting the overall survival of HCC patients treated with Sorafenib, although its performance remained poor. Further studies are needed to refine the current ability to predict the outcome of HCC patients undergoing Sorafenib.
KW - Cohort study
KW - Hepatocellular carcinoma
KW - Prognosis
KW - Sorafenib
KW - Survival
KW - Cohort study
KW - Hepatocellular carcinoma
KW - Prognosis
KW - Sorafenib
KW - Survival
UR - http://hdl.handle.net/10807/204550
U2 - 10.1016/j.dld.2020.12.001
DO - 10.1016/j.dld.2020.12.001
M3 - Article
SN - 1590-8658
VL - 53
SP - 1011
EP - 1019
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
ER -